Jose L. Lopez-Ribot to DNA-Binding Proteins
This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about DNA-Binding Proteins.
Connection Strength
0.607
-
Uppuluri P, Pierce CG, Thomas DP, Bubeck SS, Saville SP, Lopez-Ribot JL. The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell. 2010 Oct; 9(10):1531-7.
Score: 0.287
-
Saville SP, Thomas DP, L?pez Ribot JL. A role for Efg1p in Candida albicans interactions with extracellular matrices. FEMS Microbiol Lett. 2006 Mar; 256(1):151-8.
Score: 0.210
-
Ramage G, VandeWalle K, L?pez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett. 2002 Aug 27; 214(1):95-100.
Score: 0.041
-
Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998 Nov; 42(11):2932-7.
Score: 0.032
-
Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother. 2006 Oct; 50(10):3312-6.
Score: 0.014
-
Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006 Apr 01; 193(7):1014-22.
Score: 0.013
-
Perea S, L?pez-Ribot JL, Kirkpatrick WR, McAtee RK, Santill?n RA, Mart?nez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001 Oct; 45(10):2676-84.
Score: 0.010